Why the study?
Is red blood cell platelet-activating factor acetylhydrolase (PAF-AH) activity reduced in patients with a history of cerebral thrombosis compared to healthy controls?
Is red blood cell platelet-activating factor acetylhydrolase (PAF-AH) activity reduced in patients with a history of cerebral thrombosis compared to healthy controls?
Patients with a history of cerebral thrombosis have significantly lower RBC PAF-AH activity, which correlates with reduced RBC deformability and may predispose to ischemic diseases.
Lower RBC PAF-AH activity was associated with cerebral thrombosis; hypothesis-generating and requires prospective validation before clinical use.
Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, PAF) is a bioactive phospholipid and inactivated by a specific enzyme, PAF acetylhydrolase (PAF-AH). We have measured PAF-AH activity in red blood cells (RBCs) from patients with a history of cerebral thrombosis and age-matched healthy controls. The activities in 34 patients and 34 controls were 1.29 +/- 0.28 and 1.64 +/- 0.26 nmol/10(9) RBCs/min (or, 30.0 +/- 5.8 and 35.1 +/- 4.7 nmol/g protein/min) (mean +/- SD), respectively, and the difference was significant (p less than 0.001). In patients, RBC PAF-AH activity correlated positively with RBC filterability, an index of RBC deformability (r = +0.501, p less than 0.05). The RBC activity may play a role in scavenging oxidation products of membrane phospholipids. Lower RBC PAF-AH activity may predispose to ischemic diseases by disturbing microcirculatory behavior of the RBCs.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: